Brief: Biogen And Stoke Therapeutics Announce First Patient Dosed In Phase 3 Emperor Study Of Zorevunersen
11/08/2025 12:11
Aug 11 (Reuters) - Biogen Inc BIIB.O: BIOGEN AND STOKE THERAPEUTICS ANNOUNCE FIRST PATIENT DOSED IN PHASE 3 EMPEROR STUDY OF ZOREVUNERSEN, A POTENTIAL DISEASE-MODIFYING TREATMENT FOR DRAVET SYNDROME Source text: ID:nGNEc1tpxL Further company coverage: BIIB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Stoke Therapeutics
See all newsBrief: Stoke Therapeutics Announces Inducement Grants
U.S. STOCKS ON THE MOVE-Moderna, O-I Glass, Aveanna Healthcare
U.S. STOCKS ON THE MOVE-NetEase, Werewolf Therapeutics, JP Morgan
U.S. STOCKS ON THE MOVE-Ubiquiti, BJ's Wholesale, Arbutus
U.S. STOCKS ON THE MOVE-Gold miners, Ross Stores, Stoke Therapeutics